InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-1.4%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Hoppenot Herve, Chairman & CEO. Officer active across 1 company, notably INCYTE CORP. Cumulatively, 13 disclosures have been recorded. History available since 2 July 2021. The latest transaction was disclosed on 1 April 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations13 total
66,899 shares0Common StockSEC:0001628280-25-016570:0
41,025 shares0Common StockSEC:0000879169-24-000133:0
41,723 shares@ US$59.0248.1% of flowCommon StockSEC:0000879169-24-000116:0
41,577 shares0Common StockSEC:0000879169-24-000060:0
43,184 shares0Common StockSEC:0001209191-23-042547:0
43,467 shares@ US$62.0851.9% of flowCommon StockSEC:0001209191-23-041510:0
29,196 shares0Common StockSEC:0001209191-23-004564:0
60,433 shares0Common StockSEC:0001209191-22-041071:0
2,227 shares0Common StockSEC:0001209191-21-066406:0
2,227 shares0Common StockSEC:0001209191-21-066406
44,264 shares0Common StockSEC:0001209191-21-045789
44,264 shares0Common StockSEC:0001209191-21-045789:0
10,442 sharesCommon StockSEC:0001209191-16-090537:0
13 of 13 declarations
About Hoppenot Herve
Herve Hoppenot serves as Chairman and CEO of Incyte Corp. He leads the company in developing innovative treatments for cancer and other diseases. Incyte is a biopharmaceutical company specializing in drug research and development. Mr. Hoppenot's experience in the pharmaceutical sector enables him to guide the company's strategy and innovation.
